Investor Presentaiton
Pharma Segment Revenue Structure Optimization
Ao De Jin
You Di Er
You Li Tong
Bang Ting
Yan Hu Ning
Past
Revenue Structure Changed as
Product Portfolio Optimization
Now
Revenue mainly contributed by:
•
•
•
mRNA COVID-19 vaccine: help to against COVID-19
in Hong Kong, Macau and Taiwan
Han Li Kang (Rituximab Injection): the first biosimilar
product approved in China
Han Qu You (Transtuzumab Injection): the first mAb
product approved in both China and the EU
Su Ke Xin (Avatrombopag Tablets): the first oral
drug approved to treat low blood platelet count in adults
with long-lasting (chronic) liver disease (CLD)
Artesunate and other anti-malarial product: have
saved more than 48 million lives
苏可收
HERER
LEMS
Henlius
注射用曲憲珠单抗
马来酸阿伐曲泊帕片
Doptelet
Artesun
M
18
匹伐他汀钙片
【非布司他片:
Future
•
Examples of core innovative product pipeline
Received NMPA approval for the first
innovative biological drug Serplulimab MSI-H
indication. The NDA for sqNSCLC, ES-SCLC
and ESCC was accepted by NMPA
°
Yi Kai Da (Axicabtagene Ciloleucel Injection)
became the first CAR-T cell therapy product
approved for launch in China in June 2021
long-lasting
DaxibotulinumtoxinA product
RT002, Bcl-2 inhibitor, ORIN1001, MEK1/2
inhibitor, FCN-159.View entire presentation